Innovation developed from plants and plant-derived material can be substantial and includes biotech crops, food...
Medicinal Cannabis in Australia | Part 4: Protecting plant-related innovation in Australia
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Grant Shoebridge PhD
Grant has over 15 years experience providing pharma, biopharma and biotech intellectual property services, and is renowned in his field. Grant is listed in IAM Patent 1000 as a world leading prosecution stand-out.
See Grant's full profile
Medicinal Cannabis in Australia | Part 3: Beyond PBR – IP rights and medicinal cannabis
As medicinal cannabis (MC) becomes more established in the medicinal sector due to regulatory and attitudinal changes,...
The Full Federal Court overturns AI inventorship in Australia
An enlarged bench of the Full Court of the Federal Court has overturned a first instance decision, reported here, by...
Gene Therapy 22/23 Budget Announcement Big News for Australian Patients, and for Novartis
The Australian treasurer, Josh Frydenberg used his budget speech yesterday to make several announcements in relation...
Breaking News: Full Court strikes down two PTEs
A PTE must be based on the earliest approved product even when it is a competitor product.
On 18 March 2022, the Full Court gave highly awaited judgments in two cases[1] concerning the validity of patent term...
PTE Alert: Recent cases create fertile ground for PTE challenges
In the last year, two significant Federal Court decisions, reported here and here have exposed key flaws in the...
Is best practice for patent validity in Australia an impossible task?
The evolution of jurisprudence in Australia can have far reaching implications for legal practitioners in every...
Merck and Pfizer pneumococcal conjugate vaccine settlement prolongs uncertainty regarding Australian product claims
Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement...
The DABUS decision makes Australia look like a champion of innovation, not a chump
Originally published in the IAM Saturday Opinion on 11 September 2021. Australia was recently thrust into the global...
Did pharmaceutical innovation contribute to the AI inventor controversy in Australia?
Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an...
PTEs in Australia – more hard lessons for patentees from the Federal Court
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when...
World-first decision: Artificial Intelligence recognised as a patent inventor under Australian law
The Australian Federal Court in Thaler v Commissioner of Patents [2021] FCA 879 (30 July 2021) has determined that an...
The one-minute guide to life sciences patent eligibility in the US, Europe and Australia
Pearce IP recently reported on the Full Court of the Federal Court decision in Ariosa Diagnostics, Inc v Sequenom, Inc...
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia
Diagnostic tests that rely on a naturally occurring phenomenon patent eligible in Australia On 18 June 2021, the Full...
Patent term extension alert: Australian Patent Office scorched by the Federal Court!
Common sense prevails in new interpretation of pharmaceutical extension of term legislation
In September 2020, Pearce IP reported on a significant Australian Patent Office decision, which held that a patent...
Australian Patent system review: an ineffectual hand-waving exercise?
A missed opportunity to introduce an alternative second-tier patent system!
Pearce IP recently reported on recommendations made by an independent review into the Australian patent system to...